Background: Patients with IgG-deficiency often suffer from repeated bacterial infections with S. pneumoniae. Since there is a lack of knowledge regarding whether IgG-deficient patients would benefit from conjugate pneumococcal vaccination, we set out to evaluate the effect of Prevnar13 vaccination in IgG- and/or IgG-deficient patients.
Method: We designed a small pilot-study including IgG- and/or IgG-deficient patients (n=10) and age- and sex-matched healthy controls (n=10). Serum, plasma and heparin-blood were collected prior to vaccination, as well as 1, 2 and 4weeks post vaccination, and the levels of opsonophagocytic activity (Opa) titers and anti-pneumococcal IgG-antibodies were analyzed.
Results: Patients generally had lower Opa-titers than controls for most serotypes, but they exhibited an almost normal vaccine response to serotypes 6A and 6B. Notably, 5/10 patients showed vaccine-response to at least one serotype. Most patients reached the presumably protective levels of Opa-titers ≥8 and anti-pneumococcal IgG levels of 0.35µg/ml by 4weeks post-vaccination for a majority of the serotypes.
Conclusion: Our results show that vaccination of IgG-deficient patients with Prevnar13 is likely to have a clinical benefit. Our initial findings will provide a framework for future vaccine-trials in this vulnerable patient group. Registered at www.clinicaltrials.gov as NCT01847781.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2017.03.097 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The common variable immunodeficiency IgM repertoire narrowly recognizes erythrocyte and platelet glycans.
J Allergy Clin Immunol
September 2024
Division of Immunology and Allergy, Children's Hospital of Philadelphia, Philadelphia, Pa; Department of Pediatrics, Perelman School of Medicine, Philadelphia, Pa; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa. Electronic address:
Article Synopsis
- Autoimmune cytopenias (AICs) are found in patients with common variable immunodeficiency (CVID) who have IgG deficiency, but the specific autoantibodies involved remain unclear.
- This study aimed to investigate the characteristics and origins of IgM autoantibodies associated with AICs in CVID patients, using various methods like glycan arrays and sequencing.
- The results showed that IgM autoantibodies target specific erythrocytic and platelet antigens and are produced mainly by a distinct subset of B cells activated by certain T cell signals, suggesting a key role in the autoimmune processes related to AICs.
Unusual Polyclonal IgM in an IgG Deficient Patient with Autoimmune Lymphoproliferative Syndrome: A Case Study and Literature Review.
Ann Clin Lab Sci
November 2022
Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA
Autoimmune lymphoproliferative syndrome (ALPS) is a rare genetic disease caused germline mutation of gene, gene encoding Fas ligand or gene. However, in 20% of all ALPS patients, genetic defect is unknown. We presented a case of a 20-year-old male with a history of autoimmune lymphoproliferative syndrome (ALPS; confirmed by genetic study) who came to our medical center with a concern for malignancy.
View Article and Find Full Text PDFLow Admission Immunoglobulin G Levels Predict Poor Outcome in Patients with Mild-to-Critical COVID-19: A Prospective, Single-Center Study.
J Epidemiol Glob Health
December 2021
First Department of Critical Care Medicine and Pulmonary Services, School of Medicine, National and Kapodistrian University of Athens, "Evangelismos" Hospital, 45-47 Ipsilantou St, 10676, Athens, Greece.
Article Synopsis
- - The study investigates the relationship between immunoglobulin (Ig) levels and clinical outcomes in COVID-19 patients, focusing specifically on IgG, IgM, and IgA levels at hospital admission.
- - Results show that patients who survived had significantly higher IgG levels compared to those who did not survive, indicating a link between low IgG levels and higher mortality.
- - The findings suggest that low IgG levels upon admission may independently predict a higher risk of death in COVID-19 patients.
Immunoglobulin deficiency as an indicator of disease severity in patients with COVID-19.
Am J Physiol Lung Cell Mol Physiol
April 2021
Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany.
Despite the pandemic status of COVID-19, there is limited information about host risk factors and treatment beyond supportive care. Immunoglobulin G (IgG) could be a potential treatment target. Our aim was to determine the incidence of IgG deficiency and associated risk factors in a cohort of 62 critically ill patients with COVID-19 admitted to two German ICUs (72.
View Article and Find Full Text PDFDe-escalating rituximab dose results in stability of clinical, radiological, and serum neurofilament levels in multiple sclerosis.
Mult Scler
July 2021
Multiple sclerosis Center, Department of Neurology, Neurocenter of Southern Switzerland (NSI), Ospedale Civico, Lugano, Switzerland; Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.
Background: Phase II and observational studies support the use of rituximab in multiple sclerosis. Standard protocols are lacking, but studies suggest comparable efficacy between low- and high-dose regimens.
Objective: To evaluate effectiveness and safety of de-escalating rituximab dose from 1000 to 500 mg/6 months in multiple sclerosis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!